Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABP 692
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ABP 692 is an investigational biosimilar to Ocrevus (ocrelizumab), a recombinant humanized glycosylated immunoglobulin G1 (IgG1) monoclonal antibody that targets CD20, a protein expressed on the surface of B-cells. By binding to CD20, ABP 692 depletes B-cells, which play a key role in the pathogenesis of multiple sclerosis. The drug is being developed for the treatment of relapsing-remitting multiple sclerosis and is currently in Phase 3 clinical trials to demonstrate pharmacokinetic and pharmacodynamic similarity to ocrelizumab[1][3][4][5][7].
- Other names
- ABP 692ABP692ABP-692
02
Targets
Beyond the preview
Go deeper on ABP 692.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABP 692.